Construction of phosphorylatable chimeric monoclonal antibody CC49

International Journal of Oncology

Volumn 13, Issue 1, 1998, Pages 115-120

  Lin, Lei ^a   Gillies, Stephen D ^b   Lan, Yan ^b   Izotova, Lara ^a   Wei, W U ^a   Schlom, Jeffrey ^c   Pestka, Sidney ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Lexigen Pharmaceuticals Corp   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cAMP dependent protein kinase; cAMP dependent protein kinase recognition site; Cancer diagnosis; Cancer therapy; Chimeric antibody; Monoclonal antibody; Protein kinase; Tumor associated antigens

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIGEN; CHIMERIC ANTIBODY; CYCLIC AMP DEPENDENT PROTEIN KINASE; MONOCLONAL ANTIBODY CC49; PROTEIN;

ANIMAL CELL; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CHIMERA; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0031835053     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.1.115     Document Type: Article

References (29)

1. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG and Podoloff DA: Phase II radioimmunotherapy trial with 1311-CC49 in colorectal cancer. Cancer 73: 1057-1066, 1994.
2. Perkins AC, Vincent RM, Wastie ML, Denton GW, Amar S, and Hardcastle JD: Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity. Nucl Med Commun 15: 981-990, 1994.
3. Goldenberg DM: Monoclonal antibodies in cancer detection and therapy. Am J Med 94: 297-312, 1993.
4. Colcher D, Horan Hand P, Nuti M and Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78: 3199-3203, 1981.
5. Nuti M, Teramoto YA, Mariani-Costantini R, Horan Hand P, Colcher D and Schlom J: A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor associated antigen in human mammary carcinoma cell populations. Int J Cancer 29: 539-545, 1982.
6. Stramignoni D, Bowen R, Atkinson B and Schlom J: Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 31: 543-552, 1983.
7. Thor A, Ohuchi N, Szpak CA, Johnson WW and Schlom J: The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 46: 3118-3124, 1986.
8. Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM and Schlom J: Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 47: 1185-1189, 1987.
9. Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, et al: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MoAb B72.3. Int J Cancer 39: 50-59, 1987.
10. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM and Schlom J: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218-4224, 1987.
11. Carrasquillo J, Sugarbaker P, Colcher D, Reynolds J, Esteban J, Begent G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J and Larson SM: Radioimmunoscintigraphy of colon cancer with iodine 131-labeled B72.3 monoclonal antibody. J Nucl Med 29: 1022-1030, 1988.
12. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguch P and Schlom J: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumorassociated glycoprotein 72 antigen. Cancer Res 48: 4588-4596, 1988.
13. Molinolo A, Simpson JF, Thor A and Schlom J: Enhanced tumor binding using immunohistochemical analyses by second-generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 51: 1291-1298, 1990.
14. Scott AM, Divgi CR, Kemeny N, Finn RD, Pentlow K, Schlom J and Larson SM: Radioimmunotherapy with I-131 labeled monoclonal antibody CC49 in colorectal cancer. Eur J Nucl Med 8: 709, 1992.
15. 131I-CC49 in colorectal cancer. Cancer 73 (Suppl): 1055-1066, 1994.
16. Li B-L, Langer JA, Schwartz B and Pestka S: Creation of phosphorylation sites in proteins: construction of a phosphorylatable human interferon α. Proc Natl Acad Sci USA 86: 558-562, 1989.
17. Zhao X-X, Li B-L, Langer JA, Van Piper G and Pestka S: Construction and phosphorylation of a fusion protein Hu-IFN-αA/γ. Anal Biochem 178: 342-347, 1989.
18. Mariano TM and Pestka S: Receptor-binding studies. In: Cytokines-A Practical Approach. Balkwill FR (ed.) Oxford University Press, Oxford, pp95-108, 1991.
19. Wang P, Izotova L, Mariano TM, Donnelly RJ and Pestka S: Construction and activity of phosphorylatable human interferon-αB2 and interferon-αA/D. J Interferon Res 14: 41-46, 1994.
20. Lin L, Daugherty B, Schlom J and Pestka S: Construction of phosphorylatable monoclonal antibody to a tumor associated antigen. Cancer Res 56: 4250-4254, 1996.
21. Gillies SD, Lo K-M and Wesolowski JS: High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 125: 191-202, 1989.
22. Gillies SD, Young D, Lo K-M, Foley SF and Reisfeld RA: Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma 10: 347-356, 1991.
23. De Martino JA, Daugherty BL, Law MF, Cuca GL, Alves K, Silberklang M and Mark GE: Rapid humanization and expression of murine monoclonal antibodies. Antibody Immunoconj Radiopharmaceut 4: 829-835, 1991.
24. Pestka S: Studies in transfer ribonucleic acid-ribosome complex. J Biol Chem 247: 4669-4678, 1972.
25. Lin L: Construction of phosphorylatable monoclonal antibodies to a tumor-associated antigen. Ph.D. Thesis submitted to the Graduate School-New Brunswick, Rutgers, The State University of New Jersey, and the Graduate School of Biomedical Sciences, Robert Wood Johnson Medical School, 1997.
26. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB and Schlom J: Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235: 895-898, 1987.
27. Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S and Schlom J: Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α interferon treatment. Cancer Res 44: 3208-3214, 1984.
28. Guadagni F, Schlom J, Johnson WW, Szpak CZ, Goldstein D, Smalley R, Simpson JF, Borden EC, Pestka S and Greiner JW: Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst 81: 502-512, 1989.
29. Scatchard G: Attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.